Form 4: Cero Therapeutics Holdings Director Converts Preferred Stock to Common Stock

Kathleen LaPorte, a director of Cero Therapeutics Holdings, converted 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock on September 25, 2024.

Summary

• On September 25, 2024, Kathleen LaPorte, a director at Cero Therapeutics Holdings, converted 50 shares of Series A Preferred Stock into 965,997 shares of Common Stock.
• The conversion was executed at a rate of 19,320 common shares per $1,000 of Series A Preferred Stock due to adjustments in the terms of the preferred stock.
• LaPorte also directly owns 5,828 shares of Common Stock.
• LaPorte is the trustee of the Kathleen LaPorte Revocable Trust, which holds 965,997 shares of Common Stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing a stock conversion, with no inherent positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions and provides transparency to the market regarding the holdings and transactions of company insiders.

Stakeholder Impact

• The conversion of preferred stock to common stock may slightly dilute existing shareholders' equity.

Key Dates

Keywords

Cero Therapeutics Holdings, Kathleen LaPorte, Series A Preferred Stock, Common Stock, Conversion, Director, Beneficial Ownership, Form 4